PDCD1 and type 1 diabetes mellitus: The possible mechanisms are as follows: (1) Loss of immune regulation: ICIs enhance the antitumor immune response by inhibiting the PD-1/PD-L1 pathway, but this may lead to unintended adverse effects, including T1DM, as immune regulation may be lost [16].